insight
✂️ 성형 🏥 중증 🌐 전체
← 뒤로

Oncological outcomes of I125low dose brachytherapy in localized prostate cancer.

1/5 보강
The Canadian journal of urology 📖 저널 OA 4% 2025: 0/11 OA 2026: 1/10 OA 2025~2026 2026 Vol.33(1) p. 93-103
Retraction 확인
출처
PubMed DOI

PICO 자동 추출 (휴리스틱, conf 2/4)

유사 논문
P · Population 대상 환자/모집단
499 patients with localized prostate cancer treated with I125 LDR real-time brachytherapy between 2003 and 2021.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Cancer-specific survival and overall survival were 99.8% and 98.0%, respectively. [CONCLUSIONS] LDR with I125 has excellent long-term oncological outcomes for patients with low and intermediate-risk prostate cancer, in particular, patients achieving a nadir PSA <0.2 ng/mL at 5 years post-treatment.

Chéchile Toniolo G, Jornet N, Rojas J, Tejedor N, Carrara S, Maccagno A

PubMed ↗ DOI ↗ BibTeX ↓ RIS ↓
📝 환자 설명용 한 줄

[BACKGROUND] Low-dose rate (LDR) prostate brachytherapy is a recommended treatment of localized prostate cancer in current guidelines.

🔬 핵심 임상 통계 (초록에서 자동 추출 — 원문 검증 권장)
  • p-value p = 0.0001
  • p-value p = 0.003
  • 추적기간 70.5 months

이 논문을 인용하기

↓ .bib ↓ .ris
APA Chéchile Toniolo G, Jornet N, et al. (2026). Oncological outcomes of I125low dose brachytherapy in localized prostate cancer.. The Canadian journal of urology, 33(1), 93-103. https://doi.org/10.32604/cju.2026.069182
MLA Chéchile Toniolo G, et al.. "Oncological outcomes of I125low dose brachytherapy in localized prostate cancer.." The Canadian journal of urology, vol. 33, no. 1, 2026, pp. 93-103.
PMID 41800505 ↗
DOI 10.32604/cju.2026.069182

Abstract

[BACKGROUND] Low-dose rate (LDR) prostate brachytherapy is a recommended treatment of localized prostate cancer in current guidelines. The study aimed to determine biochemical relapse-free survival (BRFS) in patients treated with dynamic real-time low-dose rate (LDR) brachytherapy using Iodine 125 (I125).

[METHODS] We retrospectively reviewed 499 patients with localized prostate cancer treated with I125 LDR real-time brachytherapy between 2003 and 2021. The mean patient age was 65 years (range: 45-84 years). Based on the National Comprehensive Cancer Network (NCCN) risk classification, 230 patients (46.1%) were categorized as low risk, 235 (47.1%) as intermediate risk, and 34 (6.8%) as high risk. Gleason scores were distributed as follows: 3+3 in 283 cases (56.7%), 3+4 in 157 cases (31.5%), 4+3 in 46 cases (9.2%), and 4+4 in 13 cases (2.6%). The mean follow-up was 70.5 months.

[RESULTS] Tumor relapse was observed in 47 patients (9.4%) over a mean follow-up period of 6.26 years (SD 4.16). Local recurrence within the prostate occurred in 20 cases (4%). Patients with nadir PSA <0.2 ng/mL at 5 years of follow-up had a significantly lower incidence of tumor recurrence (3%) compared to those with a nadir PSA >0.2 ng/mL (21.9%) (p = 0.0001). Biochemical relapse-free (BRFS) rates at 5, 10 and 15 years were 96%, 91.5% and 88.9%, respectively. When stratified by NCCCN risk groups, 5-year BRFS was 96% in low risk, 98% in intermediate risk and 85% in high risk patients (p = 0.003). In multivariate analysis, only age at the time of brachytherapy (p = 0.009), initial PSA (p = 0.007) and Gleason grade (p = 0.007) were significantly associated with tumor recurrence. Cancer-specific survival and overall survival were 99.8% and 98.0%, respectively.

[CONCLUSIONS] LDR with I125 has excellent long-term oncological outcomes for patients with low and intermediate-risk prostate cancer, in particular, patients achieving a nadir PSA <0.2 ng/mL at 5 years post-treatment.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반